Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2014

Open Access 01-12-2014 | Original investigation

Chemerin is a novel biomarker of acute coronary syndrome but not of stable angina pectoris

Authors: Qingwei Ji, Yingzhong Lin, Zhishan Liang, Kunwu Yu, Yuyang Liu, Zhe Fang, Ling Liu, Ying Shi, Qiutang Zeng, Chao Chang, Meng Chai, Yujie Zhou

Published in: Cardiovascular Diabetology | Issue 1/2014

Login to get access

Abstract

Background

Recent evidence demonstrated that the circulating adipokines were associated with the onset of acute coronary syndrome (ACS) including unstable angina pectoris (UAP) and acute myocardial infarction (AMI). As a novel adipokine, chemerin has been related to atherosclerosis and the presence of coronary artery disease. However, the plasma levels of chemerin in patients with ACS have yet to be investigated.

Methods

Plasma levels of chemerin and adiponectin were measured by an enzyme-linked immunosorbent assay (ELISA) in 60 patients with stable angina pectoris (SAP), 60 patients with UAP, 60 patients with AMI and 40 control patients. Left ventricular end-diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF) were measured using a GE ViVid E7 ultrasonography machine, and the severity of coronary stenosis in patients was estimated with a Gensini coronary score following coronary angiography.

Results

Plasma chemerin levels were significantly higher in ACS patients than in the control and SAP groups, while plasma adiponectin levels were significantly lower in ACS patients than the control group. A correlation analysis revealed that plasma chemerin levels were positively correlated with the levels of C-reactive protein (CRP) (r = 0.29, P < 0.01) and LVEDD (r = 0.27, P < 0.01) but negatively correlated with LVEF (r = -0.45, P < 0.01) and that plasma adiponectin levels were positively correlated with LVEF (r = 0.53, P < 0.01) but negatively correlated with CRP (r = -0.33, P < 0.01) and LVEDD (r = -0.30, P < 0.01). Although significant correlations between chemerin, adiponectin and BMI or the Gensini coronary score were found in patients with SAP, neither chemerin nor adiponectin was correlated with BMI and the Gensini coronary score in patients with ACS. Furthermore, both chemerin (OR 1.103, 95% CI 1.065 to 1.142; P = 0.001) and adiponectin (OR 0.871, 95% CI 0.776 to 0.970; P = 0.018) were independently associated with the presence of ACS.

Conclusions

Chemerin is a novel biomarker of acute coronary syndrome but not of stable angina pectoris.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ghattas A, Griffiths HR, Devitt A, Lip GY, Shantsila E: Monocytes in coronary artery disease and atherosclerosis where are we now?. J Am Coll Cardiol. 2013, 62: 1541-1551. 10.1016/j.jacc.2013.07.043.CrossRefPubMed Ghattas A, Griffiths HR, Devitt A, Lip GY, Shantsila E: Monocytes in coronary artery disease and atherosclerosis where are we now?. J Am Coll Cardiol. 2013, 62: 1541-1551. 10.1016/j.jacc.2013.07.043.CrossRefPubMed
2.
go back to reference Libby P: Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013, 368: 2004-2013. 10.1056/NEJMra1216063.CrossRefPubMed Libby P: Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013, 368: 2004-2013. 10.1056/NEJMra1216063.CrossRefPubMed
3.
go back to reference Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003, 108: 1664-1672. 10.1161/01.CIR.0000087480.94275.97.CrossRefPubMed Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003, 108: 1664-1672. 10.1161/01.CIR.0000087480.94275.97.CrossRefPubMed
4.
go back to reference Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O’Neill WW: Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med. 2000, 343: 915-922. 10.1056/NEJM200009283431303.CrossRefPubMed Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O’Neill WW: Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med. 2000, 343: 915-922. 10.1056/NEJM200009283431303.CrossRefPubMed
5.
go back to reference Tedgui A, Mallat Z: Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006, 86: 515-581. 10.1152/physrev.00024.2005.CrossRefPubMed Tedgui A, Mallat Z: Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006, 86: 515-581. 10.1152/physrev.00024.2005.CrossRefPubMed
6.
go back to reference Ntaios G, Gatselis NK, Makaritsis K, Dalekos GN: Adipokines as mediators of endothelial function and atherosclerosis. Atherosclerosis. 2013, 227: 216-221. 10.1016/j.atherosclerosis.2012.12.029.CrossRefPubMed Ntaios G, Gatselis NK, Makaritsis K, Dalekos GN: Adipokines as mediators of endothelial function and atherosclerosis. Atherosclerosis. 2013, 227: 216-221. 10.1016/j.atherosclerosis.2012.12.029.CrossRefPubMed
7.
go back to reference Syed Ikmal SI, Zaman Huri H, Vethakkan SR, Wan Ahmad WA: Potential biomarkers of insulin resistance and atherosclerosis in type 2 diabetes mellitus patients with coronary artery disease. Int J Endocrinol. 2013, 2013: 698567-10.1155/2013/698567.PubMedCentralCrossRefPubMed Syed Ikmal SI, Zaman Huri H, Vethakkan SR, Wan Ahmad WA: Potential biomarkers of insulin resistance and atherosclerosis in type 2 diabetes mellitus patients with coronary artery disease. Int J Endocrinol. 2013, 2013: 698567-10.1155/2013/698567.PubMedCentralCrossRefPubMed
8.
go back to reference Asterholm IW, Rutkowski JM, Fujikawa T, Cho YR, Fukuda M, Tao C, Wang ZV, Gupta RK, Elmquist JK, Scherer PE: Elevated resistin levels induce central leptin resistance and increased atherosclerotic progression in mice. Diabetologia. 2014, 57: 1209-1218. 10.1007/s00125-014-3210-3.PubMedCentralCrossRefPubMed Asterholm IW, Rutkowski JM, Fujikawa T, Cho YR, Fukuda M, Tao C, Wang ZV, Gupta RK, Elmquist JK, Scherer PE: Elevated resistin levels induce central leptin resistance and increased atherosclerotic progression in mice. Diabetologia. 2014, 57: 1209-1218. 10.1007/s00125-014-3210-3.PubMedCentralCrossRefPubMed
9.
go back to reference Zhou F, Pan Y, Huang Z, Jia Y, Zhao X, Chen Y, Diao J, Wan Q, Cui X: Visfatin induces cholesterol accumulation in macrophages through up-regulation of scavenger receptor-A and CD36. Cell Stress Chaperones. 2013, 18: 643-652. 10.1007/s12192-013-0417-z.PubMedCentralCrossRefPubMed Zhou F, Pan Y, Huang Z, Jia Y, Zhao X, Chen Y, Diao J, Wan Q, Cui X: Visfatin induces cholesterol accumulation in macrophages through up-regulation of scavenger receptor-A and CD36. Cell Stress Chaperones. 2013, 18: 643-652. 10.1007/s12192-013-0417-z.PubMedCentralCrossRefPubMed
10.
go back to reference Wan Q, Cui X, Shao J, Zhou F, Jia Y, Sun X, Zhao X, Chen Y, Diao J, Zhang L: Beijing ambient particle exposure accelerates atherosclerosis in ApoE knockout mice by upregulating visfatin expression. Cell Stress Chaperones. 2014, 19: 715-724. 10.1007/s12192-014-0499-2.PubMedCentralCrossRefPubMed Wan Q, Cui X, Shao J, Zhou F, Jia Y, Sun X, Zhao X, Chen Y, Diao J, Zhang L: Beijing ambient particle exposure accelerates atherosclerosis in ApoE knockout mice by upregulating visfatin expression. Cell Stress Chaperones. 2014, 19: 715-724. 10.1007/s12192-014-0499-2.PubMedCentralCrossRefPubMed
11.
go back to reference Alam SE, Nasser SS, Fernainy KE, Habib AA, Badr KF: Cytokine imbalance in acute coronary syndrome. Curr Opin Pharmacol. 2004, 4: 166-170. 10.1016/j.coph.2003.10.011.CrossRefPubMed Alam SE, Nasser SS, Fernainy KE, Habib AA, Badr KF: Cytokine imbalance in acute coronary syndrome. Curr Opin Pharmacol. 2004, 4: 166-170. 10.1016/j.coph.2003.10.011.CrossRefPubMed
12.
go back to reference Liu SW, Qiao SB, Yuan JS, Liu DQ: Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf). 2009, 71: 202-207. 10.1111/j.1365-2265.2008.03453.x.CrossRef Liu SW, Qiao SB, Yuan JS, Liu DQ: Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf). 2009, 71: 202-207. 10.1111/j.1365-2265.2008.03453.x.CrossRef
13.
go back to reference Basati G, Razavi AE, Abdi S, Sarrafzedegan N: Association of plasma leptin, homocysteine and nitric oxide levels with the presence and unstability of coronary artery disease. Biomark Med. 2014, 8: 405-412. 10.2217/bmm.13.131.CrossRefPubMed Basati G, Razavi AE, Abdi S, Sarrafzedegan N: Association of plasma leptin, homocysteine and nitric oxide levels with the presence and unstability of coronary artery disease. Biomark Med. 2014, 8: 405-412. 10.2217/bmm.13.131.CrossRefPubMed
14.
go back to reference Huang CL, Wu YW, Wu CC, Lin L, Wu YC, Hsu PY, Jong YS, Yang WS: Association between serum adipocyte fatty-acid binding protein concentrations, left ventricular function and myocardial perfusion abnormalities in patients with coronary artery disease. Cardiovasc Diabetol. 2013, 12: 105-10.1186/1475-2840-12-105.PubMedCentralCrossRefPubMed Huang CL, Wu YW, Wu CC, Lin L, Wu YC, Hsu PY, Jong YS, Yang WS: Association between serum adipocyte fatty-acid binding protein concentrations, left ventricular function and myocardial perfusion abnormalities in patients with coronary artery disease. Cardiovasc Diabetol. 2013, 12: 105-10.1186/1475-2840-12-105.PubMedCentralCrossRefPubMed
15.
go back to reference van Stijn CM, Kim J, Barish GD, Tietge UJ, Tangirala RK: Adiponectin expression protects against angiotensin II-mediated inflammation and accelerated atherosclerosis. PLoS One. 2014, 9: e86404-10.1371/journal.pone.0086404.PubMedCentralCrossRefPubMed van Stijn CM, Kim J, Barish GD, Tietge UJ, Tangirala RK: Adiponectin expression protects against angiotensin II-mediated inflammation and accelerated atherosclerosis. PLoS One. 2014, 9: e86404-10.1371/journal.pone.0086404.PubMedCentralCrossRefPubMed
16.
go back to reference Wilson SR, Sabatine MS, Wiviott SD, Ray KK, De Lemos JA, Zhou S, Rifai N, Cannon CP, Morrow DA: Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). Am Heart J. 2011, 161: 1147-1155. 10.1016/j.ahj.2011.02.014.CrossRefPubMed Wilson SR, Sabatine MS, Wiviott SD, Ray KK, De Lemos JA, Zhou S, Rifai N, Cannon CP, Morrow DA: Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). Am Heart J. 2011, 161: 1147-1155. 10.1016/j.ahj.2011.02.014.CrossRefPubMed
17.
go back to reference Cheng M, Hashmi S, Mao X, Zeng QT: Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome. Can J Cardiol. 2008, 24: 385-390. 10.1016/S0828-282X(08)70602-0.PubMedCentralCrossRefPubMed Cheng M, Hashmi S, Mao X, Zeng QT: Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome. Can J Cardiol. 2008, 24: 385-390. 10.1016/S0828-282X(08)70602-0.PubMedCentralCrossRefPubMed
18.
go back to reference Rizk NM, El-Menyar A, Marei I, Sameer M, Musad T, Younis D, Farag F, Basem N, Al-Ali K, Al Suwaidi J: Association of adiponectin gene polymorphism (+T45G) with acute coronary syndrome and circulating adiponectin levels. Angiology. 2013, 64: 257-265. 10.1177/0003319712455497.CrossRefPubMed Rizk NM, El-Menyar A, Marei I, Sameer M, Musad T, Younis D, Farag F, Basem N, Al-Ali K, Al Suwaidi J: Association of adiponectin gene polymorphism (+T45G) with acute coronary syndrome and circulating adiponectin levels. Angiology. 2013, 64: 257-265. 10.1177/0003319712455497.CrossRefPubMed
19.
go back to reference Otake H, Shite J, Shinke T, Watanabe S, Tanino Y, Ogasawara D, Sawada T, Hirata K, Yokoyama M: Relation between plasma adiponectin, high-sensitivity C-reactive protein, and coronary plaque components in patients with acute coronary syndrome. Am J Cardiol. 2008, 101: 1-7. 10.1016/j.amjcard.2007.07.041.CrossRefPubMed Otake H, Shite J, Shinke T, Watanabe S, Tanino Y, Ogasawara D, Sawada T, Hirata K, Yokoyama M: Relation between plasma adiponectin, high-sensitivity C-reactive protein, and coronary plaque components in patients with acute coronary syndrome. Am J Cardiol. 2008, 101: 1-7. 10.1016/j.amjcard.2007.07.041.CrossRefPubMed
20.
go back to reference Mittal A, Gupta MD, Meennahalli Palleda G, Vyas A, Tyagi S: Relationship of plasma adiponectin levels with acute coronary syndromes and coronary lesion severity in north Indian population. ISRN Cardiol. 2013, 2013: 854815-10.1155/2013/854815.PubMedCentralCrossRefPubMed Mittal A, Gupta MD, Meennahalli Palleda G, Vyas A, Tyagi S: Relationship of plasma adiponectin levels with acute coronary syndromes and coronary lesion severity in north Indian population. ISRN Cardiol. 2013, 2013: 854815-10.1155/2013/854815.PubMedCentralCrossRefPubMed
21.
go back to reference Kim JY, Choi EY, Mun HS, Min PK, Yoon YW, Lee BK, Hong BK, Rim SJ, Kwon HM: Usefulness of metabolic syndrome score in the prediction of angiographic coronary artery disease severity according to the presence of diabetes mellitus: relation with inflammatory markers and adipokines. Cardiovasc Diabetol. 2013, 12: 140-10.1186/1475-2840-12-140.PubMedCentralCrossRefPubMed Kim JY, Choi EY, Mun HS, Min PK, Yoon YW, Lee BK, Hong BK, Rim SJ, Kwon HM: Usefulness of metabolic syndrome score in the prediction of angiographic coronary artery disease severity according to the presence of diabetes mellitus: relation with inflammatory markers and adipokines. Cardiovasc Diabetol. 2013, 12: 140-10.1186/1475-2840-12-140.PubMedCentralCrossRefPubMed
22.
go back to reference Nakamura Y, Shimada K, Fukuda D, Shimada Y, Ehara S, Hirose M, Kataoka T, Kamimori K, Shimodozono S, Kobayashi Y, Yoshiyama M, Takeuchi K, Yoshikawa J: Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart. 2004, 90: 528-533. 10.1136/hrt.2003.011114.PubMedCentralCrossRefPubMed Nakamura Y, Shimada K, Fukuda D, Shimada Y, Ehara S, Hirose M, Kataoka T, Kamimori K, Shimodozono S, Kobayashi Y, Yoshiyama M, Takeuchi K, Yoshikawa J: Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart. 2004, 90: 528-533. 10.1136/hrt.2003.011114.PubMedCentralCrossRefPubMed
23.
go back to reference Zhang H, Mo X, Hao Y, Huang J, Lu X, Cao J, Gu D: Adiponectin levels and risk of coronary heart disease: a meta-analysis of prospective studies. Am J Med Sci. 2013, 345: 455-461. 10.1097/MAJ.0b013e318262dbef.CrossRefPubMed Zhang H, Mo X, Hao Y, Huang J, Lu X, Cao J, Gu D: Adiponectin levels and risk of coronary heart disease: a meta-analysis of prospective studies. Am J Med Sci. 2013, 345: 455-461. 10.1097/MAJ.0b013e318262dbef.CrossRefPubMed
24.
go back to reference Persson J, Lindberg K, Gustafsson TP, Eriksson P, Paulsson-Berne G, Lundman P: Low plasma adiponectin concentration is associated with myocardial infarction in young individuals. J Intern Med. 2010, 268: 194-205. 10.1111/j.1365-2796.2010.02247.x.CrossRefPubMed Persson J, Lindberg K, Gustafsson TP, Eriksson P, Paulsson-Berne G, Lundman P: Low plasma adiponectin concentration is associated with myocardial infarction in young individuals. J Intern Med. 2010, 268: 194-205. 10.1111/j.1365-2796.2010.02247.x.CrossRefPubMed
25.
go back to reference Sook Lee E, Park SS, Kim E, Sook Yoon Y, Ahn HY, Park CY, Ho Yun Y, Woo Oh S: Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis. Int J Epidemiol. 2013, 42: 1029-1039. 10.1093/ije/dyt087.CrossRefPubMed Sook Lee E, Park SS, Kim E, Sook Yoon Y, Ahn HY, Park CY, Ho Yun Y, Woo Oh S: Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis. Int J Epidemiol. 2013, 42: 1029-1039. 10.1093/ije/dyt087.CrossRefPubMed
26.
go back to reference Nagpal S, Patel S, Jacobe H, DiSepio D, Ghosn C, Malhotra M, Teng M, Duvic M, Chandraratna RA: Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin. J Invest Dermatol. 1997, 109: 91-95. 10.1111/1523-1747.ep12276660.CrossRefPubMed Nagpal S, Patel S, Jacobe H, DiSepio D, Ghosn C, Malhotra M, Teng M, Duvic M, Chandraratna RA: Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin. J Invest Dermatol. 1997, 109: 91-95. 10.1111/1523-1747.ep12276660.CrossRefPubMed
27.
go back to reference Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, Migeotte I, Brézillon S, Tyldesley R, Blanpain C, Detheux M, Mantovani A, Sozzani S, Vassart G, Parmentier M, Communi D: Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003, 198: 977-985. 10.1084/jem.20030382.PubMedCentralCrossRefPubMed Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, Migeotte I, Brézillon S, Tyldesley R, Blanpain C, Detheux M, Mantovani A, Sozzani S, Vassart G, Parmentier M, Communi D: Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003, 198: 977-985. 10.1084/jem.20030382.PubMedCentralCrossRefPubMed
28.
go back to reference Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, Muruganandan S, Sinal CJ: Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007, 282: 28175-28188. 10.1074/jbc.M700793200.CrossRefPubMed Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, Muruganandan S, Sinal CJ: Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007, 282: 28175-28188. 10.1074/jbc.M700793200.CrossRefPubMed
29.
go back to reference Roman AA, Parlee SD, Sinal CJ: Chemerin: a potential endocrine link between obesity and type 2 diabetes. Endocrine. 2012, 42: 243-251. 10.1007/s12020-012-9698-8.CrossRefPubMed Roman AA, Parlee SD, Sinal CJ: Chemerin: a potential endocrine link between obesity and type 2 diabetes. Endocrine. 2012, 42: 243-251. 10.1007/s12020-012-9698-8.CrossRefPubMed
30.
go back to reference Yamawaki H, Kameshima S, Usui T, Okada M, Hara Y: A novel adipocytokine, chemerin exerts anti-inflammatory roles in human vascular endothelial cells. Biochem Biophys Res Commun. 2012, 423: 152-157. 10.1016/j.bbrc.2012.05.103.CrossRefPubMed Yamawaki H, Kameshima S, Usui T, Okada M, Hara Y: A novel adipocytokine, chemerin exerts anti-inflammatory roles in human vascular endothelial cells. Biochem Biophys Res Commun. 2012, 423: 152-157. 10.1016/j.bbrc.2012.05.103.CrossRefPubMed
31.
go back to reference Yan Q, Zhang Y, Hong J, Gu W, Dai M, Shi J, Zhai Y, Wang W, Li X, Ning G: The association of serum chemerin level with risk of coronary artery disease in Chinese adults. Endocrine. 2012, 41: 281-288. 10.1007/s12020-011-9550-6.CrossRefPubMed Yan Q, Zhang Y, Hong J, Gu W, Dai M, Shi J, Zhai Y, Wang W, Li X, Ning G: The association of serum chemerin level with risk of coronary artery disease in Chinese adults. Endocrine. 2012, 41: 281-288. 10.1007/s12020-011-9550-6.CrossRefPubMed
32.
go back to reference Xiaotao L, Xiaoxia Z, Yue X, Liye W: Serum chemerin levels are associated with the presence and extent of coronary artery disease. Coron Artery Dis. 2012, 23: 412-416. 10.1097/MCA.0b013e3283576a60.CrossRefPubMed Xiaotao L, Xiaoxia Z, Yue X, Liye W: Serum chemerin levels are associated with the presence and extent of coronary artery disease. Coron Artery Dis. 2012, 23: 412-416. 10.1097/MCA.0b013e3283576a60.CrossRefPubMed
33.
go back to reference Lin X, Tang X, Jiang Q, Liu Q, Lin Z, Lin J, Chen L, Hong H: Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with type 2 diabetes. Clin Lab. 2012, 58: 539-544.PubMed Lin X, Tang X, Jiang Q, Liu Q, Lin Z, Lin J, Chen L, Hong H: Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with type 2 diabetes. Clin Lab. 2012, 58: 539-544.PubMed
34.
go back to reference Herová M, Schmid M, Gemperle C, Loretz C, Hersberger M: Low dose aspirin is associated with plasma chemerin levels and may reduce adipose tissue inflammation. Atherosclerosis. 2014, 235: 256-262. 10.1016/j.atherosclerosis.2014.05.912.CrossRefPubMed Herová M, Schmid M, Gemperle C, Loretz C, Hersberger M: Low dose aspirin is associated with plasma chemerin levels and may reduce adipose tissue inflammation. Atherosclerosis. 2014, 235: 256-262. 10.1016/j.atherosclerosis.2014.05.912.CrossRefPubMed
35.
go back to reference Gensini GG: A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983, 51: 606-10.1016/S0002-9149(83)80105-2.CrossRefPubMed Gensini GG: A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983, 51: 606-10.1016/S0002-9149(83)80105-2.CrossRefPubMed
36.
go back to reference Kim HM, Lee BW, Song YM, Kim WJ, Chang HJ, Choi DH, Yu HT, Kang E, Cha BS, Lee HC: Potential association between coronary artery disease and the inflammatory biomarker YKL-40 in asymptomatic patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2012, 11: 84-10.1186/1475-2840-11-84.PubMedCentralCrossRefPubMed Kim HM, Lee BW, Song YM, Kim WJ, Chang HJ, Choi DH, Yu HT, Kang E, Cha BS, Lee HC: Potential association between coronary artery disease and the inflammatory biomarker YKL-40 in asymptomatic patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2012, 11: 84-10.1186/1475-2840-11-84.PubMedCentralCrossRefPubMed
37.
go back to reference Okamoto Y, Ishii S, Croce K, Katsumata H, Fukushima M, Kihara S, Libby P, Minami S: Adiponectin inhibits macrophage tissue factor, a key trigger of thrombosis in disrupted atherosclerotic plaques. Atherosclerosis. 2013, 226: 373-377. 10.1016/j.atherosclerosis.2012.12.012.PubMedCentralCrossRefPubMed Okamoto Y, Ishii S, Croce K, Katsumata H, Fukushima M, Kihara S, Libby P, Minami S: Adiponectin inhibits macrophage tissue factor, a key trigger of thrombosis in disrupted atherosclerotic plaques. Atherosclerosis. 2013, 226: 373-377. 10.1016/j.atherosclerosis.2012.12.012.PubMedCentralCrossRefPubMed
38.
go back to reference Venojärvi M, Wasenius N, Manderoos S, Heinonen OJ, Hernelahti M, Lindholm H, Surakka J, Lindström J, Aunola S, Atalay M, Eriksson JG: Nordic walking decreased circulating chemerin and leptin concentrations in middle-aged men with impaired glucose regulation. Ann Med. 2013, 45: 162-170. 10.3109/07853890.2012.727020.CrossRefPubMed Venojärvi M, Wasenius N, Manderoos S, Heinonen OJ, Hernelahti M, Lindholm H, Surakka J, Lindström J, Aunola S, Atalay M, Eriksson JG: Nordic walking decreased circulating chemerin and leptin concentrations in middle-aged men with impaired glucose regulation. Ann Med. 2013, 45: 162-170. 10.3109/07853890.2012.727020.CrossRefPubMed
39.
go back to reference Meric M, Soylu K, Avci B, Yuksel S, Gulel O, Yenercag M, Coksevim M, Uzun A: Evaluation of plasma chemerin levels in patients with non-dipper blood pressure patterns. Med Sci Monit. 2014, 20: 698-705. 10.12659/MSM.890784.PubMedCentralCrossRefPubMed Meric M, Soylu K, Avci B, Yuksel S, Gulel O, Yenercag M, Coksevim M, Uzun A: Evaluation of plasma chemerin levels in patients with non-dipper blood pressure patterns. Med Sci Monit. 2014, 20: 698-705. 10.12659/MSM.890784.PubMedCentralCrossRefPubMed
40.
go back to reference Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R, Farkas S, Scherer MN, Schäffler A, Aslanidis C, Schölmerich J, Buechler C: Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf). 2010, 72: 342-348. 10.1111/j.1365-2265.2009.03664.x.CrossRef Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R, Farkas S, Scherer MN, Schäffler A, Aslanidis C, Schölmerich J, Buechler C: Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf). 2010, 72: 342-348. 10.1111/j.1365-2265.2009.03664.x.CrossRef
41.
go back to reference Derosa G, Cicero AF, Carbone A, Querci F, Fogari E, D’Angelo A, Maffioli P: Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. Eur J Pharm Sci. 2014, 1: 26-33. 10.1016/j.ejps.2013.08.031.CrossRef Derosa G, Cicero AF, Carbone A, Querci F, Fogari E, D’Angelo A, Maffioli P: Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. Eur J Pharm Sci. 2014, 1: 26-33. 10.1016/j.ejps.2013.08.031.CrossRef
42.
go back to reference Van de Voorde J, Pauwels B, Boydens C, Decaluwé K: Adipocytokines in relation to cardiovascular disease. Metabolism. 2013, 62: 1513-1521. 10.1016/j.metabol.2013.06.004.CrossRefPubMed Van de Voorde J, Pauwels B, Boydens C, Decaluwé K: Adipocytokines in relation to cardiovascular disease. Metabolism. 2013, 62: 1513-1521. 10.1016/j.metabol.2013.06.004.CrossRefPubMed
43.
go back to reference Nakamura K, Fuster JJ, Walsh K: Adipokines: a link between obesity and cardiovascular disease. J Cardiol. 2014, 63: 250-259. 10.1016/j.jjcc.2013.11.006.PubMedCentralCrossRefPubMed Nakamura K, Fuster JJ, Walsh K: Adipokines: a link between obesity and cardiovascular disease. J Cardiol. 2014, 63: 250-259. 10.1016/j.jjcc.2013.11.006.PubMedCentralCrossRefPubMed
44.
go back to reference Gao X, Mi S, Zhang F, Gong F, Lai Y, Gao F, Zhang X, Wang L, Tao H: Association of chemerin mRNA expression in human epicardial adipose tissue with coronary atherosclerosis. Cardiovasc Diabetol. 2011, 10: 87-10.1186/1475-2840-10-87.PubMedCentralCrossRefPubMed Gao X, Mi S, Zhang F, Gong F, Lai Y, Gao F, Zhang X, Wang L, Tao H: Association of chemerin mRNA expression in human epicardial adipose tissue with coronary atherosclerosis. Cardiovasc Diabetol. 2011, 10: 87-10.1186/1475-2840-10-87.PubMedCentralCrossRefPubMed
Metadata
Title
Chemerin is a novel biomarker of acute coronary syndrome but not of stable angina pectoris
Authors
Qingwei Ji
Yingzhong Lin
Zhishan Liang
Kunwu Yu
Yuyang Liu
Zhe Fang
Ling Liu
Ying Shi
Qiutang Zeng
Chao Chang
Meng Chai
Yujie Zhou
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2014
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-014-0145-4

Other articles of this Issue 1/2014

Cardiovascular Diabetology 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.